Contact
searchSearch
HMP Global
Login

Oncology

Featured

FDA Approval
FDA Approves Amivantamab and Hyaluronidase for Previously Treated Head and Neck Squamous Cell Carcinoma
11/06/2026
Stephanie Holland
Results from the phase 1b/2 OrigAMI-4 trial supported FDA accelerated approval of subcutaneous amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck squamous cell carcinoma, introducing a dual...
Results from the phase 1b/2 OrigAMI-4 trial supported FDA accelerated approval of subcutaneous amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck squamous cell carcinoma, introducing a dual...
Results from the phase 1b/2...
11/06/2026
Oncology
News
Varegacestat Advances Toward European Approval for Desmoid Tumors Following RINGSIDE Survival Benefit
11/05/2026
Emily Estrada
Based on results from the phase 3 RINGSIDE trial, the European Medicines Agency has validated the marketing authorization application for varegacestat in adults with desmoid tumors, following significant improvements in progression-free...
Based on results from the phase 3 RINGSIDE trial, the European Medicines Agency has validated the marketing authorization application for varegacestat in adults with desmoid tumors, following significant improvements in progression-free...
Based on results from the phase...
11/05/2026
Oncology
Paul Swiecicki, MD
Videos
Subcutaneous Amivantamab Triplet Achieves High Response Rates in Recurrent or Metastatic Head and Neck Cancer
11/05/2026
Paul Swiecicki, MD, discusses results from cohort 5 of the OrigAMI-4 trial evaluating subcutaneous amivantamab plus pembrolizumab and carboplatin in first-line recurrent or metastatic head and neck squamous cell carcinoma, highlighting...
Paul Swiecicki, MD, discusses results from cohort 5 of the OrigAMI-4 trial evaluating subcutaneous amivantamab plus pembrolizumab and carboplatin in first-line recurrent or metastatic head and neck squamous cell carcinoma, highlighting...
Paul Swiecicki, MD, discusses...
11/05/2026
Oncology
News
Lirafugratinib Receives NCCN Category 2A Recommendation Following FDA Approval in FGFR2-Altered Cholangiocarcinoma
11/05/2026
Emily Estrada
Following FDA approval supported by the phase 1/2 ReFocus trial, lirafugratinib has been added to the NCCN Guidelines as a Category 2A preferred subsequent-line treatment option for patients with cholangiocarcinoma harboring FGFR2 fusions or...
Following FDA approval supported by the phase 1/2 ReFocus trial, lirafugratinib has been added to the NCCN Guidelines as a Category 2A preferred subsequent-line treatment option for patients with cholangiocarcinoma harboring FGFR2 fusions or...
Following FDA approval supported...
11/05/2026
Oncology
Andrea Necchi, MD
Videos
ENERGIZE Trial Demonstrates No EFS Benefit With Perioperative Nivolumab Plus Chemotherapy in Muscle-Invasive Bladder Cancer
11/05/2026
Andrea Necchi, MD
Andrea Necchi, MD, discusses final results from the phase 3 ENERGIZE trial evaluating perioperative nivolumab plus gemcitabine and cisplatin in muscle-invasive bladder cancer, highlighting the absence of significant event-free survival or...
Andrea Necchi, MD, discusses final results from the phase 3 ENERGIZE trial evaluating perioperative nivolumab plus gemcitabine and cisplatin in muscle-invasive bladder cancer, highlighting the absence of significant event-free survival or...
Andrea Necchi, MD, discusses...
11/05/2026
Oncology
Kohei Shitara, MD
Videos
Arcotatug Tavatecan Significantly Improves PFS in CLDN18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
11/05/2026
Kohei Shitara, MD
Kohei Shitara, MD, discusses results from the phase 3 G-HOPE-001 trial evaluating arcotatug tavatecan versus chemotherapy in previously treated CLDN18.2-positive advanced gastric and gastroesophageal junction cancer, highlighting significant...
Kohei Shitara, MD, discusses results from the phase 3 G-HOPE-001 trial evaluating arcotatug tavatecan versus chemotherapy in previously treated CLDN18.2-positive advanced gastric and gastroesophageal junction cancer, highlighting significant...
Kohei Shitara, MD, discusses...
11/05/2026
Oncology
Kohei Shitara, MD
Videos
Updated HERIZON-GEA-01 Results Demonstrate Overall Survival Benefit With Zanidatamab-Based Regimens in HER2-Positive Gastroesophageal Cancer
11/05/2026
Kohei Shitara, MD
Kohei Shitara, MD, discusses updated results from the phase 3 HERIZON-GEA-01 trial evaluating zanidatamab plus chemotherapy, with or without tislelizumab, in HER2-positive gastroesophageal cancer, highlighting improved overall survival with...
Kohei Shitara, MD, discusses updated results from the phase 3 HERIZON-GEA-01 trial evaluating zanidatamab plus chemotherapy, with or without tislelizumab, in HER2-positive gastroesophageal cancer, highlighting improved overall survival with...
Kohei Shitara, MD, discusses...
11/05/2026
Oncology
Wenchao Han, PhD
Podcasts
Artificial Intelligence Advances Lymphoma Diagnosis, Biomarker Identification, and Precision Treatment
11/04/2026
Wenchao Han, PhD
Wenchao Han, PhD, discusses the emerging role of artificial intelligence (AI) in lymphoma diagnosis and management, highlighting AI-assisted histopathologic classification, multimodal biomarker analysis, and treatment response prediction, as...
Wenchao Han, PhD, discusses the emerging role of artificial intelligence (AI) in lymphoma diagnosis and management, highlighting AI-assisted histopathologic classification, multimodal biomarker analysis, and treatment response prediction, as...
Wenchao Han, PhD, discusses the...
11/04/2026
Oncology
Ajai Chari, MD
Videos
Bispecific and Trispecific Antibodies Advance Earlier Treatment of Relapsed or Refractory Multiple Myeloma
11/04/2026
Ajai Chari, MD
Ajai Chari, MD, discusses advances in bispecific and trispecific antibody therapy for multiple myeloma, highlighting improved progression-free survival outcomes from recent phase 3 trials, emerging combination regimens, earlier treatment...
Ajai Chari, MD, discusses advances in bispecific and trispecific antibody therapy for multiple myeloma, highlighting improved progression-free survival outcomes from recent phase 3 trials, emerging combination regimens, earlier treatment...
Ajai Chari, MD, discusses...
11/04/2026
Oncology
Mateo Mejia Saldarriaga, MD
Videos
AQUILA Findings Fuel Debate Over Treatment Intensification in High-Risk Smoldering Myeloma
11/04/2026
Mateo Mejia Saldarriaga, MD
Mateo Mejia Saldarriaga, MD, discusses treatment strategies for high-risk smoldering multiple myeloma, highlighting the progression-free survival benefits and limitations of single-agent daratumumab and lenalidomide, findings from the AQUILA...
Mateo Mejia Saldarriaga, MD, discusses treatment strategies for high-risk smoldering multiple myeloma, highlighting the progression-free survival benefits and limitations of single-agent daratumumab and lenalidomide, findings from the AQUILA...
Mateo Mejia Saldarriaga, MD,...
11/04/2026
Oncology
News
Pumitamig Plus Chemotherapy Shows Antitumor Activity Regardless of Brain Metastasis Status
11/04/2026
Emily Estrada
Results from two phase 2 trials demonstrated encouraging intracranial responses with pumitamig plus chemotherapy in patients with small cell lung cancer and triple-negative breast cancer with brain metastases, supporting further investigation...
Results from two phase 2 trials demonstrated encouraging intracranial responses with pumitamig plus chemotherapy in patients with small cell lung cancer and triple-negative breast cancer with brain metastases, supporting further investigation...
Results from two phase 2 trials...
11/04/2026
Oncology

Videos

Paul Swiecicki, MD
Videos
Subcutaneous Amivantamab Triplet Achieves High Response Rates in Recurrent or Metastatic Head and Neck Cancer
11/05/2026
Paul Swiecicki, MD, discusses results from cohort 5 of the OrigAMI-4 trial evaluating subcutaneous amivantamab plus pembrolizumab and carboplatin in first-line recurrent or metastatic head and neck squamous cell carcinoma, highlighting...
Paul Swiecicki, MD, discusses results from cohort 5 of the OrigAMI-4 trial evaluating subcutaneous amivantamab plus pembrolizumab and carboplatin in first-line recurrent or metastatic head and neck squamous cell carcinoma, highlighting...
Paul Swiecicki, MD, discusses...
11/05/2026
Oncology
Andrea Necchi, MD
Videos
ENERGIZE Trial Demonstrates No EFS Benefit With Perioperative Nivolumab Plus Chemotherapy in Muscle-Invasive Bladder Cancer
11/05/2026
Andrea Necchi, MD
Andrea Necchi, MD, discusses final results from the phase 3 ENERGIZE trial evaluating perioperative nivolumab plus gemcitabine and cisplatin in muscle-invasive bladder cancer, highlighting the absence of significant event-free survival or...
Andrea Necchi, MD, discusses final results from the phase 3 ENERGIZE trial evaluating perioperative nivolumab plus gemcitabine and cisplatin in muscle-invasive bladder cancer, highlighting the absence of significant event-free survival or...
Andrea Necchi, MD, discusses...
11/05/2026
Oncology
Kohei Shitara, MD
Videos
Arcotatug Tavatecan Significantly Improves PFS in CLDN18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
11/05/2026
Kohei Shitara, MD
Kohei Shitara, MD, discusses results from the phase 3 G-HOPE-001 trial evaluating arcotatug tavatecan versus chemotherapy in previously treated CLDN18.2-positive advanced gastric and gastroesophageal junction cancer, highlighting significant...
Kohei Shitara, MD, discusses results from the phase 3 G-HOPE-001 trial evaluating arcotatug tavatecan versus chemotherapy in previously treated CLDN18.2-positive advanced gastric and gastroesophageal junction cancer, highlighting significant...
Kohei Shitara, MD, discusses...
11/05/2026
Oncology
Kohei Shitara, MD
Videos
Updated HERIZON-GEA-01 Results Demonstrate Overall Survival Benefit With Zanidatamab-Based Regimens in HER2-Positive Gastroesophageal Cancer
11/05/2026
Kohei Shitara, MD
Kohei Shitara, MD, discusses updated results from the phase 3 HERIZON-GEA-01 trial evaluating zanidatamab plus chemotherapy, with or without tislelizumab, in HER2-positive gastroesophageal cancer, highlighting improved overall survival with...
Kohei Shitara, MD, discusses updated results from the phase 3 HERIZON-GEA-01 trial evaluating zanidatamab plus chemotherapy, with or without tislelizumab, in HER2-positive gastroesophageal cancer, highlighting improved overall survival with...
Kohei Shitara, MD, discusses...
11/05/2026
Oncology
Ajai Chari, MD
Videos
Bispecific and Trispecific Antibodies Advance Earlier Treatment of Relapsed or Refractory Multiple Myeloma
11/04/2026
Ajai Chari, MD
Ajai Chari, MD, discusses advances in bispecific and trispecific antibody therapy for multiple myeloma, highlighting improved progression-free survival outcomes from recent phase 3 trials, emerging combination regimens, earlier treatment...
Ajai Chari, MD, discusses advances in bispecific and trispecific antibody therapy for multiple myeloma, highlighting improved progression-free survival outcomes from recent phase 3 trials, emerging combination regimens, earlier treatment...
Ajai Chari, MD, discusses...
11/04/2026
Oncology
Mateo Mejia Saldarriaga, MD
Videos
AQUILA Findings Fuel Debate Over Treatment Intensification in High-Risk Smoldering Myeloma
11/04/2026
Mateo Mejia Saldarriaga, MD
Mateo Mejia Saldarriaga, MD, discusses treatment strategies for high-risk smoldering multiple myeloma, highlighting the progression-free survival benefits and limitations of single-agent daratumumab and lenalidomide, findings from the AQUILA...
Mateo Mejia Saldarriaga, MD, discusses treatment strategies for high-risk smoldering multiple myeloma, highlighting the progression-free survival benefits and limitations of single-agent daratumumab and lenalidomide, findings from the AQUILA...
Mateo Mejia Saldarriaga, MD,...
11/04/2026
Oncology
Vivek Subbiah, MD
Videos
Tumor-Agnostic Therapies Advance Precision Oncology Through Comprehensive Biomarker Testing
11/04/2026
Vivek Subbiah, MD
Vivek Subbiah, MD, discusses advances in tumor-agnostic precision oncology, highlighting comprehensive genomic profiling, actionable molecular alterations, and biomarker-directed therapies across cancer types, as well as the importance of...
Vivek Subbiah, MD, discusses advances in tumor-agnostic precision oncology, highlighting comprehensive genomic profiling, actionable molecular alterations, and biomarker-directed therapies across cancer types, as well as the importance of...
Vivek Subbiah, MD, discusses...
11/04/2026
Oncology
Joseph Mikhael, MD
Videos
Optimizing Treatment Intensity and Dosing in Older and Frail Patients With Multiple Myeloma
11/03/2026
Joseph Mikhael, MD, MEd, FRCPC
Joseph Mikhael, MD, discusses individualized treatment strategies for older and frail patients with multiple myeloma, highlighting comprehensive frailty assessment, dose optimization of lenalidomide, bortezomib, and dexamethasone, and...
Joseph Mikhael, MD, discusses individualized treatment strategies for older and frail patients with multiple myeloma, highlighting comprehensive frailty assessment, dose optimization of lenalidomide, bortezomib, and dexamethasone, and...
Joseph Mikhael, MD, discusses...
11/03/2026
Oncology
Daniel King, MD, PhD
Videos
Guiding Treatment Selection and Response Assessment in Metastatic Pancreatic Cancer
11/03/2026
Daniel King, MD, PhD
Daniel King, MD, PhD, reviews the clinical decision-making behind the management of a patient with suspected metastatic pancreatic cancer, highlighting the role of molecular profiling in guiding treatment selection and clinical trial...
Daniel King, MD, PhD, reviews the clinical decision-making behind the management of a patient with suspected metastatic pancreatic cancer, highlighting the role of molecular profiling in guiding treatment selection and clinical trial...
Daniel King, MD, PhD, reviews...
11/03/2026
Oncology
Efrat Dotan, MD; Mary Larse, MSN, RN, OCN; Meredith Pelster, MD, MSCI
Videos
Clinical Perspectives: A Case-Based Discussion of Targeted Therapy in Metastatic Pancreatic Cancer
11/02/2026
Efrat Dotan, MD; Mary Larsen, MSN, RN, OCN; Meredith Pelster, MD
In this case-based discussion, experts examine the phase 3 RASolute 302 efficacy and safety data for daraxonrasib, an FDA-approved RAS inhibitor for metastatic pancreatic adenocarcinoma (mPDAC). The panelists discuss how to interpret the...
In this case-based discussion, experts examine the phase 3 RASolute 302 efficacy and safety data for daraxonrasib, an FDA-approved RAS inhibitor for metastatic pancreatic adenocarcinoma (mPDAC). The panelists discuss how to interpret the...
In this case-based discussion,...
11/02/2026
Oncology

Insights From the ASCO Annual Meeting

News
First-in-Class Hepcidin Inhibitor DISC-0974 Demonstrates Activity in Myelofibrosis-Associated Anemia
07/09/2026
Stephanie Holland
Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...
Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...
Results from the ongoing, phase...
07/09/2026
Oncology
News
Imetelstat Maintains Overall Survival Advantage Over Best Available Therapy in JAK Inhibitor–Relapsed or Refractory Myelofibrosis
07/09/2026
Stephanie Holland
Updated results from a post hoc analysis demonstrated that imetelstat continued to improve overall survival compared with best available therapy in patients with JAK inhibitor relapsed or refractory myelofibrosis, despite substantial changes...
Updated results from a post hoc analysis demonstrated that imetelstat continued to improve overall survival compared with best available therapy in patients with JAK inhibitor relapsed or refractory myelofibrosis, despite substantial changes...
Updated results from a post hoc...
07/09/2026
Oncology
Ramaswamy Govindan, MD
Videos
Adjuvant Erlotinib Following Complete Resection of EGFR-Mutant Non-Small Cell Lung Cancer Improves Disease Free Survival But Not Overall Survival
06/29/2026
Ramaswamy Govindan, MD
Ramaswamy Govindan, MD, discusses results from the ALCHEMIST trial evaluating adjuvant erlotinib in resected EGFR-mutant non–small cell lung cancer and the potential for ongoing biomarker studies to identify patients most likely to benefit...
Ramaswamy Govindan, MD, discusses results from the ALCHEMIST trial evaluating adjuvant erlotinib in resected EGFR-mutant non–small cell lung cancer and the potential for ongoing biomarker studies to identify patients most likely to benefit...
Ramaswamy Govindan, MD,...
06/29/2026
Oncology
Erika Hamilton, MD
Videos
Tucatinib Demonstrates Consistent Benefit Across First-Line HER2-Positive Metastatic Breast Cancer Populations
06/26/2026
Erika Hamilton, MD
Erika Hamilton, MD, discusses updated results from the HER2CLIMB-05 trial showing that tucatinib added to trastuzumab and pertuzumab maintenance therapy improved outcomes across multiple clinically relevant subgroups of patients with...
Erika Hamilton, MD, discusses updated results from the HER2CLIMB-05 trial showing that tucatinib added to trastuzumab and pertuzumab maintenance therapy improved outcomes across multiple clinically relevant subgroups of patients with...
Erika Hamilton, MD, discusses...
06/26/2026
Oncology
Bjørn Henning Grønberg, MD, PhD
Videos
Concurrent Radiotherapy, Chemotherapy, and Durvalumab Does Not Improve Outcomes in Extensive-Stage Small Cell Lung Cancer
06/26/2026
Bjørn Henning Grønberg, MD, PhD
Bjørn Henning Grønberg, MD, PhD, discusses results from a phase 3 randomized trial evaluating the addition of concurrent thoracic radiotherapy to platinum/etoposide chemotherapy plus durvalumab in patients with extensive-stage small cell lung...
Bjørn Henning Grønberg, MD, PhD, discusses results from a phase 3 randomized trial evaluating the addition of concurrent thoracic radiotherapy to platinum/etoposide chemotherapy plus durvalumab in patients with extensive-stage small cell lung...
Bjørn Henning Grønberg, MD, PhD,...
06/26/2026
Oncology
Peter O’Donnell, MD
Videos
Health-Related Quality of Life Preserved with Neoadjuvant and Adjuvant Enfortumab Vedotin plus Pembrolizumab in Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer
06/26/2026
Peter O'Donnell, MD
Peter O’Donnell, MD, of the University of Chicago, discusses health-related quality-of-life (HRQoL) findings from the phase 3 KEYNOTE-905 study evaluating perioperative enfortumab vedotin plus pembrolizumab in patients with muscle-invasive...
Peter O’Donnell, MD, of the University of Chicago, discusses health-related quality-of-life (HRQoL) findings from the phase 3 KEYNOTE-905 study evaluating perioperative enfortumab vedotin plus pembrolizumab in patients with muscle-invasive...
Peter O’Donnell, MD, of the...
06/26/2026
Oncology
Sanjay Popat, PhD, FRCP
Videos
Pralsetinib Shows Improved Response in RET Fusion–Positive Advanced or Metastatic Non–Small Cell Lung Cancer
06/25/2026
Sanjay Popat, PhD, FRCP
Sanjay Popat, PhD, FRCP, medical oncologist at The Royal Marsden Hospital in London, England, discusses results from the phase 3 AcceleRET-Lung trial evaluating first-line pralsetinib versus standard-of-care histology-specific chemotherapy...
Sanjay Popat, PhD, FRCP, medical oncologist at The Royal Marsden Hospital in London, England, discusses results from the phase 3 AcceleRET-Lung trial evaluating first-line pralsetinib versus standard-of-care histology-specific chemotherapy...
Sanjay Popat, PhD, FRCP, medical...
06/25/2026
Oncology
Walter Weber, MD
Videos
Prepectoral Implant Placement Improves Long-Term Quality of Life After Breast Reconstruction
06/24/2026
Walter Weber, MD
Walter Weber, MD, discusses results from the phase 3 PREPEC trial showing that prepectoral implant-based breast reconstruction significantly improved long-term quality of life and physical well-being compared with subpectoral reconstruction...
Walter Weber, MD, discusses results from the phase 3 PREPEC trial showing that prepectoral implant-based breast reconstruction significantly improved long-term quality of life and physical well-being compared with subpectoral reconstruction...
Walter Weber, MD, discusses...
06/24/2026
Oncology
Timothy Cloughesy, MD
Videos
Vorasidenib Maintains Durable Clinical Benefit With Consistent Safety in IDH-Mutated Glioma
06/24/2026
Timothy Cloughesy, MD
Timothy Cloughesy, MD, discusses updated results from the INDIGO trial showing durable disease control, prolonged progression-free survival, and sustained safety with vorasidenib in patients with IDH-mutant grade 2 gliomas.
Timothy Cloughesy, MD, discusses updated results from the INDIGO trial showing durable disease control, prolonged progression-free survival, and sustained safety with vorasidenib in patients with IDH-mutant grade 2 gliomas.
Timothy Cloughesy, MD, discusses...
06/24/2026
Oncology
Peter Schmid, MD, PhD
Videos
Giredestrant Improves Outcomes Regardless of Menopausal Status in Early Breast Cancer
06/24/2026
Peter Schmid, MD, PhD
Peter Schmid, MD, PhD, discusses subgroup analysis results from the lidERA trial showing that giredestrant improved invasive disease-free and distant recurrence-free survival across premenopausal and postmenopausal patients with ER-positive,...
Peter Schmid, MD, PhD, discusses subgroup analysis results from the lidERA trial showing that giredestrant improved invasive disease-free and distant recurrence-free survival across premenopausal and postmenopausal patients with ER-positive,...
Peter Schmid, MD, PhD, discusses...
06/24/2026
Oncology

Insights From the ESMO Congress

Paul Swiecicki, MD
Videos
Subcutaneous Amivantamab Triplet Achieves High Response Rates in Recurrent or Metastatic Head and Neck Cancer
11/05/2026
Paul Swiecicki, MD, discusses results from cohort 5 of the OrigAMI-4 trial evaluating subcutaneous amivantamab plus pembrolizumab and carboplatin in first-line recurrent or metastatic head and neck squamous cell carcinoma, highlighting...
Paul Swiecicki, MD, discusses results from cohort 5 of the OrigAMI-4 trial evaluating subcutaneous amivantamab plus pembrolizumab and carboplatin in first-line recurrent or metastatic head and neck squamous cell carcinoma, highlighting...
Paul Swiecicki, MD, discusses...
11/05/2026
Oncology
Andrea Necchi, MD
Videos
ENERGIZE Trial Demonstrates No EFS Benefit With Perioperative Nivolumab Plus Chemotherapy in Muscle-Invasive Bladder Cancer
11/05/2026
Andrea Necchi, MD
Andrea Necchi, MD, discusses final results from the phase 3 ENERGIZE trial evaluating perioperative nivolumab plus gemcitabine and cisplatin in muscle-invasive bladder cancer, highlighting the absence of significant event-free survival or...
Andrea Necchi, MD, discusses final results from the phase 3 ENERGIZE trial evaluating perioperative nivolumab plus gemcitabine and cisplatin in muscle-invasive bladder cancer, highlighting the absence of significant event-free survival or...
Andrea Necchi, MD, discusses...
11/05/2026
Oncology
Kohei Shitara, MD
Videos
Arcotatug Tavatecan Significantly Improves PFS in CLDN18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
11/05/2026
Kohei Shitara, MD
Kohei Shitara, MD, discusses results from the phase 3 G-HOPE-001 trial evaluating arcotatug tavatecan versus chemotherapy in previously treated CLDN18.2-positive advanced gastric and gastroesophageal junction cancer, highlighting significant...
Kohei Shitara, MD, discusses results from the phase 3 G-HOPE-001 trial evaluating arcotatug tavatecan versus chemotherapy in previously treated CLDN18.2-positive advanced gastric and gastroesophageal junction cancer, highlighting significant...
Kohei Shitara, MD, discusses...
11/05/2026
Oncology
Kohei Shitara, MD
Videos
Updated HERIZON-GEA-01 Results Demonstrate Overall Survival Benefit With Zanidatamab-Based Regimens in HER2-Positive Gastroesophageal Cancer
11/05/2026
Kohei Shitara, MD
Kohei Shitara, MD, discusses updated results from the phase 3 HERIZON-GEA-01 trial evaluating zanidatamab plus chemotherapy, with or without tislelizumab, in HER2-positive gastroesophageal cancer, highlighting improved overall survival with...
Kohei Shitara, MD, discusses updated results from the phase 3 HERIZON-GEA-01 trial evaluating zanidatamab plus chemotherapy, with or without tislelizumab, in HER2-positive gastroesophageal cancer, highlighting improved overall survival with...
Kohei Shitara, MD, discusses...
11/05/2026
Oncology
News
Pumitamig Plus Chemotherapy Shows Antitumor Activity Regardless of Brain Metastasis Status
11/04/2026
Emily Estrada
Results from two phase 2 trials demonstrated encouraging intracranial responses with pumitamig plus chemotherapy in patients with small cell lung cancer and triple-negative breast cancer with brain metastases, supporting further investigation...
Results from two phase 2 trials demonstrated encouraging intracranial responses with pumitamig plus chemotherapy in patients with small cell lung cancer and triple-negative breast cancer with brain metastases, supporting further investigation...
Results from two phase 2 trials...
11/04/2026
Oncology
News
SEZ6-Targeted Antibody-Drug Conjugate ABBV-706 Demonstrates Promising Antitumor Activity in Relapsed or Refractory Small Cell Lung Cancer
11/04/2026
Emily Estrada
Updated phase 1 results demonstrated promising antitumor activity with the SEZ6-targeted antibody-drug conjugate ABBV-706 in relapsed or refractory small cell lung cancer, with encouraging response and survival outcomes alongside exploratory...
Updated phase 1 results demonstrated promising antitumor activity with the SEZ6-targeted antibody-drug conjugate ABBV-706 in relapsed or refractory small cell lung cancer, with encouraging response and survival outcomes alongside exploratory...
Updated phase 1 results...
11/04/2026
Oncology
News
Phase 1 Trial Shows 70% Response Rate With SKB500 in Heavily Pretreated Patients With Small Cell Lung Cancer
11/04/2026
Emily Estrada
Updated results from a phase 1 trial demonstrated promising antitumor activity with the B7-H3-directed antibody-drug conjugate SKB500 in heavily pretreated patients with small cell lung cancer, with the lower dose showing more favorable...
Updated results from a phase 1 trial demonstrated promising antitumor activity with the B7-H3-directed antibody-drug conjugate SKB500 in heavily pretreated patients with small cell lung cancer, with the lower dose showing more favorable...
Updated results from a phase 1...
11/04/2026
Oncology
News
Varegacestat Significantly Improves Pain, Physical Function, and Quality of Life in Patients With Desmoid Tumors
11/04/2026
Emily Estrada
Results from RINGSIDE trial demonstrated rapid and sustained improvements in patient-reported pain, desmoid-related symptoms, physical function, and quality of life with varegacestat compared with placebo in patients with progressing desmoid...
Results from RINGSIDE trial demonstrated rapid and sustained improvements in patient-reported pain, desmoid-related symptoms, physical function, and quality of life with varegacestat compared with placebo in patients with progressing desmoid...
Results from RINGSIDE trial...
11/04/2026
Oncology
Vanda Salutari, MD, Policlinico Gemelli
Videos
BEHOLD-1: Updated Results With Mocertatug Rezetecan in Platinum-Resistant Ovarian Cancer
10/29/2026
Vanda Salutari, MD
Vanda Salutari, MD, discusses updated results from the phase 1 BEHOLD-1 trial evaluating the B7-H4-directed antibody-drug conjugate Mo-Rez in platinum-resistant ovarian cancer, highlighting durable antitumor activity, promising...
Vanda Salutari, MD, discusses updated results from the phase 1 BEHOLD-1 trial evaluating the B7-H4-directed antibody-drug conjugate Mo-Rez in platinum-resistant ovarian cancer, highlighting durable antitumor activity, promising...
Vanda Salutari, MD, discusses...
10/29/2026
Oncology
News
NETSARC+ Study Identifies Tumor Location and Size as Prognostic Factors in Patients With Desmoid Tumors
10/28/2026
Emily Estrada
Results from a large NETSARC+ registry analysis demonstrated a substantial decline in surgical management of desmoid tumors over time and identified tumor size and anatomical location as prognostic factors for progression-free survival,...
Results from a large NETSARC+ registry analysis demonstrated a substantial decline in surgical management of desmoid tumors over time and identified tumor size and anatomical location as prognostic factors for progression-free survival,...
Results from a large NETSARC+...
10/28/2026
Oncology

Live Meetings

Recent News

FDA Approval
FDA Approves Amivantamab and Hyaluronidase for Previously Treated Head and Neck Squamous Cell Carcinoma
11/06/2026
Stephanie Holland
Results from the phase 1b/2 OrigAMI-4 trial supported FDA accelerated approval of subcutaneous amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck squamous cell carcinoma, introducing a dual...
Results from the phase 1b/2 OrigAMI-4 trial supported FDA accelerated approval of subcutaneous amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck squamous cell carcinoma, introducing a dual...
Results from the phase 1b/2...
11/06/2026
Oncology
News
Varegacestat Advances Toward European Approval for Desmoid Tumors Following RINGSIDE Survival Benefit
11/05/2026
Emily Estrada
Based on results from the phase 3 RINGSIDE trial, the European Medicines Agency has validated the marketing authorization application for varegacestat in adults with desmoid tumors, following significant improvements in progression-free...
Based on results from the phase 3 RINGSIDE trial, the European Medicines Agency has validated the marketing authorization application for varegacestat in adults with desmoid tumors, following significant improvements in progression-free...
Based on results from the phase...
11/05/2026
Oncology
News
Lirafugratinib Receives NCCN Category 2A Recommendation Following FDA Approval in FGFR2-Altered Cholangiocarcinoma
11/05/2026
Emily Estrada
Following FDA approval supported by the phase 1/2 ReFocus trial, lirafugratinib has been added to the NCCN Guidelines as a Category 2A preferred subsequent-line treatment option for patients with cholangiocarcinoma harboring FGFR2 fusions or...
Following FDA approval supported by the phase 1/2 ReFocus trial, lirafugratinib has been added to the NCCN Guidelines as a Category 2A preferred subsequent-line treatment option for patients with cholangiocarcinoma harboring FGFR2 fusions or...
Following FDA approval supported...
11/05/2026
Oncology
News
Pumitamig Plus Chemotherapy Shows Antitumor Activity Regardless of Brain Metastasis Status
11/04/2026
Emily Estrada
Results from two phase 2 trials demonstrated encouraging intracranial responses with pumitamig plus chemotherapy in patients with small cell lung cancer and triple-negative breast cancer with brain metastases, supporting further investigation...
Results from two phase 2 trials demonstrated encouraging intracranial responses with pumitamig plus chemotherapy in patients with small cell lung cancer and triple-negative breast cancer with brain metastases, supporting further investigation...
Results from two phase 2 trials...
11/04/2026
Oncology
News
SEZ6-Targeted Antibody-Drug Conjugate ABBV-706 Demonstrates Promising Antitumor Activity in Relapsed or Refractory Small Cell Lung Cancer
11/04/2026
Emily Estrada
Updated phase 1 results demonstrated promising antitumor activity with the SEZ6-targeted antibody-drug conjugate ABBV-706 in relapsed or refractory small cell lung cancer, with encouraging response and survival outcomes alongside exploratory...
Updated phase 1 results demonstrated promising antitumor activity with the SEZ6-targeted antibody-drug conjugate ABBV-706 in relapsed or refractory small cell lung cancer, with encouraging response and survival outcomes alongside exploratory...
Updated phase 1 results...
11/04/2026
Oncology
News
Phase 1 Trial Shows 70% Response Rate With SKB500 in Heavily Pretreated Patients With Small Cell Lung Cancer
11/04/2026
Emily Estrada
Updated results from a phase 1 trial demonstrated promising antitumor activity with the B7-H3-directed antibody-drug conjugate SKB500 in heavily pretreated patients with small cell lung cancer, with the lower dose showing more favorable...
Updated results from a phase 1 trial demonstrated promising antitumor activity with the B7-H3-directed antibody-drug conjugate SKB500 in heavily pretreated patients with small cell lung cancer, with the lower dose showing more favorable...
Updated results from a phase 1...
11/04/2026
Oncology
News
Varegacestat Significantly Improves Pain, Physical Function, and Quality of Life in Patients With Desmoid Tumors
11/04/2026
Emily Estrada
Results from RINGSIDE trial demonstrated rapid and sustained improvements in patient-reported pain, desmoid-related symptoms, physical function, and quality of life with varegacestat compared with placebo in patients with progressing desmoid...
Results from RINGSIDE trial demonstrated rapid and sustained improvements in patient-reported pain, desmoid-related symptoms, physical function, and quality of life with varegacestat compared with placebo in patients with progressing desmoid...
Results from RINGSIDE trial...
11/04/2026
Oncology
FDA Alerts
Zanubrutinib Combination Receives FDA Priority Review Following Positive Phase 3 MANGROVE Results
11/04/2026
Stephanie Holland
Results from the phase 3 MANGROVE trial supported FDA Priority Review of zanubrutinib plus rituximab for previously untreated mantle cell lymphoma, following a significant progression-free survival benefit compared with bendamustine plus...
Results from the phase 3 MANGROVE trial supported FDA Priority Review of zanubrutinib plus rituximab for previously untreated mantle cell lymphoma, following a significant progression-free survival benefit compared with bendamustine plus...
Results from the phase 3...
11/04/2026
Oncology
News
Medicare Expands Coverage of Signatera MRD Testing for Hepatocellular Carcinoma Surveillance
11/03/2026
Stephanie Holland
Medicare coverage has been extended to serial Signatera molecular residual disease testing for surveillance of patients with early-stage hepatocellular carcinoma who have no evidence of disease following surgery, supported by real-world...
Medicare coverage has been extended to serial Signatera molecular residual disease testing for surveillance of patients with early-stage hepatocellular carcinoma who have no evidence of disease following surgery, supported by real-world...
Medicare coverage has been...
11/03/2026
Oncology
News
What to Expect at the 2026 NANETS Multidisciplinary NET Medical Symposium
11/02/2026
Janelle Bradley
The 2026 NANETS Multidisciplinary NET Medical Symposium will spotlight emerging research, evolving treatment strategies, and practical insights to advance neuroendocrine tumor care.
The 2026 NANETS Multidisciplinary NET Medical Symposium will spotlight emerging research, evolving treatment strategies, and practical insights to advance neuroendocrine tumor care.
The 2026 NANETS...
11/02/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use